Moneyball Medicine

Genialis, led by CEO Rafael Rosengarten, is one of the companies working toward a future where there are no more one-size-fits-all drugs—where, instead, every patient gets matched with the best drug for them based on their disease subtype, as measured by gene-sequence and gene-expression data. Analyzing that data—what Rosengarten calls "computational precision medicine"—is already helping drug developers identify the patients who are most likely to respond to experimental medicines. Not long  from now, the same technology could help doctors diagnose patients in the clinic, and/or feed back into drug discovery by providing more biological targets for biopharma companies to hit."Our commitment to biomarker-driven drug development is very principled," Rosengarten tells Harry. "There are some amazing drugs out there that, when they work, work miracles. But they don't work that often. Some work in maybe 15 percent of the patients or 20 percent. If you could tell which of those patients are going to respond, then a